OncoMatch/Clinical Trials/NCT06274515
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
Is NCT06274515 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies non-drug interventions for breast cancer.
This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression
Diagnosis of HER2+ ... breast cancer
Required: ESR1 expression
Diagnosis of ... HR+ (for cohort R1) ... breast cancer
Required: PR (PGR) expression
Diagnosis of ... HR+ (for cohort R1) ... breast cancer
Required: ESR1 loss
triple negative breast cancer (for cohort T1)
Required: PR (PGR) loss
triple negative breast cancer (for cohort T1)
Required: HER2 (ERBB2) wild-type
triple negative breast cancer (for cohort T1)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06274515 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 expression is a required biomarker for enrollment.
Does this trial require PGR?
Yes, PGR expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify